Source:http://linkedlifedata.com/resource/pubmed/id/10987433
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
17
|
pubmed:dateCreated |
2001-1-4
|
pubmed:abstractText |
A prodrug conjugate designed to undergo activation by enzymatic prostate specific antigen has been synthesized. The prodrug system undergoes activation with PSA or alpha-chymotrypsin, and shows selective cytotoxicity in a PSA secreting cell line.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0960-894X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
4
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1987-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading | |
pubmed:year |
2000
|
pubmed:articleTitle |
Towards enzyme activated antiprostatic agents.
|
pubmed:affiliation |
Department of Chemistry, Northeastern University, Boston, MA 02115, USA. grjones@lynx.neu.edu
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|